ライフサイエンスコーパス: cimetidine

1 have distinct selectivities for others (e.g. cimetidine).

2 ted with dexamethasone, diphenhydramine, and cimetidine.

3 ted with dexamethasone, diphenhydramine, and cimetidine.

4 Interventions: Systemic cimetidine.

5 ions such as 1-methyl-4-phenylpyridinium and cimetidine.

6 in rabbits in response to topically applied cimetidine.

7 3 with placebo and during period 2 with 0.5% cimetidine.

8 nist pyrilamine maleate or the H2 antagonist cimetidine.

9 -NAME plus pyrilamine maleate or l-NAME plus cimetidine.

10 by the histamine type-2 receptor antagonist cimetidine.

11 ch is important for the transport of PAH and cimetidine.

12 take of PAH and an 8-fold enhanced uptake of cimetidine.

13 trone sulfate as well as the basic compound, cimetidine.

14 , fipronil, strychnine, or the H2 antagonist cimetidine.

15 blocked by the histamine H2 receptor blocker cimetidine.

16 500 microM; piperonyl butoxide, 500 microM; cimetidine, 1 mM).

17 Furthermore, preadministration of cimetidine (100 microg; 5 microl; i.c.v.), the H2 histam

18 1%), famotidine (24%), sucralfate (24%), and cimetidine (12%).

19 treatment included sole treatment with oral cimetidine (15% vs 5%), topical interferon alfa-2b (0% v

20 The H2 receptor antagonist cimetidine (2 microM) blocked the effects of lower conce

21 Neither the H2 receptor antagonist cimetidine (20 microM) nor the H3 receptor antagonist th

22 nd 40 mg each day thereafter) or intravenous cimetidine (300-mg bolus and 50 mg/hr thereafter) for up

23 ntihistamines (diphenhydramine, 1 mg/kg, and cimetidine, 4 mg/kg) or placebo before rapid vancomycin

24 al biopsy and cryotherapy with adjuvant oral cimetidine (8% vs 9%), and excisional biopsy and cryothe

25 Cimetidine (a gastric ADH inhibitor) reduced acetate pro

26 purpose of this study is to evaluate whether cimetidine, a histamine H2-receptor antagonist, interfer

27 experiment validating their prediction that cimetidine, a histamine-2 (H2) receptor agonist commonly

28 ntinuous summer sunlight were calculated for cimetidine, a pharmaceutical whose reaction with (1)O(2)

29 is the first case series demonstrating that cimetidine, a readily available oral medication, can be

30 As a control they also tested the effects of cimetidine against renal carcinoma, for which it was not

31 ese effects of histamine were antagonized by cimetidine, an H2 receptor antagonist, but not by select

32 Given that previous studies have shown that cimetidine, an SLC16A5-inhibitor, prevents murine cispla

33 was calculated separately for sucralfate and cimetidine and expressed as cost per bleeding episode av

34 Two pharmaceutical compounds (cimetidine and imipramine) and one new protease inhibito

35 significantly by organic cations, including cimetidine and N1-methylnicotinamide.

36 hereas an increased risk was associated with cimetidine and other histamine H2-receptor antagonists,

37 ion of impurities in drug substances such as cimetidine and rosiglitazone, using accurate mass tandem

38 ted additional CYP inhibitors and found that cimetidine and sulfaphenazole, two CYP inhibitors that h

39 tween erythromycin and cisapride, as well as cimetidine and terfenadine, were also reproduced.

40 ted with dexamethasone, diphenhydramine, and cimetidine and then treated with continuous intravenous

41 ition, with the cyanoguanidine side chain of cimetidine and tiotidine having the strongest influence.

42 Cimetidine and tiotidine were the best inhibitors, with

43 mbination therapy consisting of dapsone with cimetidine and vitamin E to enhance drug efficacy and fr

44 nd cryotherapy with or without adjuvant oral cimetidine and/or topical interferon alfa-2b provide sat

45 Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily attributed t

46 Premedication with dexamethasone, cimetidine, and diphenhydramine is associated with a red

47 Burimamide, metiamide, cimetidine guanidine, cimetidine, and tiotidine were competitive with aldehyde

48 Prototype OCT inhibitors, including cimetidine, and type II cations (e.g., quinidine, quinin

49 the commonly used drugs: 1) metformin and 2) cimetidine; and two prototypic cationic substrates, 3) 1

50 e numerous drugs (topotecan, nitrofurantoin, cimetidine) as well as food carcinogens (2-amino-1-methy

51 Application of cimetidine at all concentrations tested inhibited inflam

52 ith anti-Fx1A, the cytochrome P450 inhibitor cimetidine blocked an increase in catalytic iron and ROS

53 diphenhydramine, loratadine, ranitidine, and cimetidine, but has modest affinity for the H(2) recepto

54 Cimetidine, but not ranitidine, inhibits gastric alcohol

55 male rats received 100 mg/kg body weight of cimetidine (cimetidine group [CimG]) or saline solution

56 lfamethoxazole), poor membrane permeability (cimetidine, colchicine) and also affinity to efflux tran

57 urine volumes, urinary sodium excretion, and cimetidine-corrected creatinine clearance were compared.

58 treatment with antihistamines pyrilamine or cimetidine decreased lung weight and severity of pneumon

59 Cimetidine decreases bone loss through reduction of oste

60 t (pyrilamine) or an H2 receptor antagonist (cimetidine) demonstrated a protective effect of histamin

61 Improgan, a cimetidine derivative which lacks activity at known hist

62 Cimetidine, diclofenac, and miconazole, known inhibitors

63 Cimetidine exerts a beneficial effect on periodontal dis

64 e empirical data are needed on the uptake of cimetidine, fluoxetine, and gemfibrozil, and other ioniz

65 lfate for a better side effects profile, and cimetidine for cost-effectiveness.

66 y significantly increased (P = 0.016) in the cimetidine group (31.1 cells/subject) versus the placebo

67 orty-six male rats were distributed into the cimetidine group (CimG: received daily intraperitoneal i

68 eceived 100 mg/kg body weight of cimetidine (cimetidine group [CimG]) or saline solution (sham group

69 served in the cimetidine rinse group; in the cimetidine group, 63.4% of bacteria in the neutrophils w

70 bone level (P < 0.05) compared to the three cimetidine groups, with a marked decrease in inflammatio

71 Burimamide, metiamide, cimetidine guanidine, cimetidine, and tiotidine were com

72 ydramine, whereas the H2 receptor antagonist cimetidine had no effect.

73 Although cimetidine had relatively small and variable effects on

74 Cimetidine has been shown to inhibit heme biosynthesis a

75 Vehicle or the H2 receptor antagonist cimetidine has no effect.

76 Topical application of cimetidine in a liposome carrier for the prevention of p

77 small hydrophilic organic substrates PAH and cimetidine in comparison to the large hydrophobic organi

78 less than 2-fold enhanced uptake of PAH and cimetidine in comparison to wild-type rOAT3, which exhib

79 bleeding and more effective than intravenous cimetidine in maintaining gastric pH of >4 in critically

80 rcing the idea that the beneficial effect of cimetidine in PD may be due to reduction of IL-6 immunol

81 Objective: To describe the successful use of cimetidine in pediatric patients with EPP.

82 The limit of detection by SF-ICP-MS for cimetidine in solution was approximately 4-20 ng x g(-1)

83 port in the literature describing the use of cimetidine in the effective treatment of an adult patien

84 nger than 18 years and treated with systemic cimetidine in the past 3 years.

85 alog of the histamine H2 receptor antagonist cimetidine, induces antinociception after intraventricul

86 histological evidence that topically active cimetidine is a potent inhibitor of P. gingivalis-elicit

87 Cimetidine is a powerful H2 receptor antagonist that eli

88 As cimetidine is an H2 receptor antagonist, the authors hyp

89 .5% with omeprazole suspension and 6.8% with cimetidine, meeting the criteria for the noninferiority

90 500 mg of disulfiram (n = 6) or 2,000 mg of cimetidine (n = 2).

91 The effect of cimetidine on ACHN derived tumors was not statistically

92 Additional studies of the use of cimetidine on osteoporosis and osteoporotic fractures ar

93 icantly attenuated compared with control and cimetidine only sites (P < 0.05).

94 tment with either the H2 receptor antagonist cimetidine or with the potassium channel blocker tetraet

95 sed risks were also observed with the use of cimetidine (OR 2.5, 95% CI 1.4-4.6) and psychotropic dru

96 al injections of 100 mg/kg of body weight of cimetidine) or the saline group (SG).

97 e studies provide evidence that topical 0.5% cimetidine oral rinse enhances the antibacterial functio

98 ent with dexamethasone, diphenhydramine, and cimetidine, patients received paclitaxel at a dose of 25

99 Cimetidine (pK(a) 6.92), a competitive inhibitor of hOCT

100 analog of the histamine receptor antagonist cimetidine, produces highly effective analgesia followin

101 Improgan, a congener of the H(2) antagonist cimetidine, produces non-opioid antinociception which is

102 he suppression was blocked by picrotoxin and cimetidine, respective antagonists to lobster GABA and h

103 hat the inhibition of A549 derived tumors by cimetidine resulted in a statistically significant effec

104 36) in bacterial killing was observed in the cimetidine rinse group; in the cimetidine group, 63.4% o

105 conducted to examine the effects of topical cimetidine rinse on neutrophil function in the gingival

106 ects rinsed twice a day with placebo or 0.5% cimetidine rinses.

107 between the l-NAME and combined l-NAME plus cimetidine sites but these sites were significantly atte

108 l sites was not significantly different from cimetidine sites.

109 In the sulfur-containing drug substance cimetidine, structurally related impurities well below t

110 Improgan is an analog of the H(2) antagonist cimetidine that does not act on known histamine receptor

111 Improgan is a derivative of cimetidine that induces non-opioid antinociception after

112 However, i.v. or i.c.v. preadministration of cimetidine, the H2-histamine receptor antagonist, failed

113 Excisional biopsy, cryotherapy, oral cimetidine, topical or injection interferon alfa-2b, and

114 35, Y341, and F362 are important for PAH and cimetidine transport by rOAT3.

115 hOCT2-mediated cimetidine transport decreased over this pH range, the c

116 rved that the residues contribute to PAH and cimetidine transport in different ways: the -OH group of

117 suspension treatment and on 50% of days with cimetidine treatment (p < .001, all trial days).

118 rial with parallel omeprazole suspension and cimetidine treatment groups.

119 We found that cimetidine treatment in a xenograft model using A549 lun

120 Cimetidine treatment in a xenograft model using ACHN ren

121 cy, the cost per bleeding episode averted of cimetidine was 6.5-fold greater than the cost per bleedi

122 Complete removal of ranitidine and cimetidine was achieved within 30 min of electrolysis at

123 As the H2 receptor antagonist cimetidine was perfused to the tissue, histamine levels

124 The Ki value of the E3 isozyme for cimetidine was the same as the in vitro dissociation con

125 ndent sample of 14 patients (seven receiving cimetidine) were mixed with 60 mL of enteral feeding in

126 secretory dose of omeprazole, ranitidine, or cimetidine, were intragastrically administered saline, a

127 on, which were reversed by the H2 antagonist cimetidine, were observed in PBMC and isolated monocytes

128 played markedly reduced transport of TEA and cimetidine while retaining transport of 1-methyl-4-pheny